Mucosal immunity in HIV controllers: the right place at the right time
- 1 May 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 6 (3) , 202-207
Abstract
The phenomenon of long-term nonprogression in HIV infection has been recognized for some time, and the ability of rare individuals, designated ‘elite controllers’, to control HIV in the absence of therapy is the focus of numerous ongoing studies. This review focuses on studies of HIV-specific immune responses in mucosal tissues as a potential correlate of immune control, with an emphasis on recently published work. Genetic studies have implicated a role for elements localized to the major histocompatibility complex (MHC) on chromosome 6 in the immune control of HIV infection. In parallel, functional studies have strongly implicated MHC class I-restricted, CD8+ T-cell responses as a major contributor to elite control. In addition, the localization of HIV-specific CD8+ and CD4+ T cells with respect to the major sites of virus replication in the body may be critical in determining clinical outcome. Recent findings suggest that MHC class I-restricted, CD8+ T cells are a major component of immune control in ‘elite controllers’. In addition, the presence of these effector cells at or near critical viral reservoirs, such as mucosal tissues, may be critical in determining their effectiveness at limiting viral replication and dissemination.Keywords
This publication has 43 references indexed in Scilit:
- Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long‐Term Nonprogressors in the US Department of Defense HIV Natural History StudyThe Journal of Infectious Diseases, 2009
- HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-CNature Genetics, 2009
- Persistent Low‐Level Viremia in HIV‐1 Elite Controllers and Relationship to Immunologic ParametersThe Journal of Infectious Diseases, 2009
- Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosisAIDS, 2009
- Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune controlBlood, 2009
- Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral InfectionScience, 2009
- HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye RecognitionJournal of Virology, 2009
- HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1Journal of Virology, 2009
- Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral TherapyJournal of Virology, 2009
- Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 StudyPLOS ONE, 2008